What COVID Spotlight Means For Pharma – In Their Own Words

Observers Weigh In On The Impact Pandemic Response Will Have On Industry's Reputation

 
• By Jessica Merrill

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 

• Source: Shutterstock

The biopharmaceutical industry has more commonly been seen as a villian in recent years, but it has played a heroic role in responding to the COVID-19 pandemic – rising to meet challenges from research and development to manufacturing, all in unprecedented timelines with new levels of collaboration and virtually unrestricted budgets. As new treatments reach patients and vaccines get closer, will there be a goodwill benefit for the industry? Scrip spoke with several industry execs and outside observers about the potential for pharma to reset its reputation. (Also see "Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity" - Scrip, 30 October, 2020.) Below are some of their responses. 

Downloadable PDF version

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.